Musculoskeletal disorders can arise as a consequence of chronic diseases such as diabetes or osteoporosis, or from acute injuries such as fractures, osteoectomy, or ischemia. These disorders lead to pain, reduced mobility, increased infection rates, inability to work/socializepoor mental health and consequently a lower quality of lifeThe prevalence of such disorders increases with age, and given our ageing population, research into the mechansims of musculoskeletal disorders to allow for the design of novel and effective therapeutics is vital, particularly since there is no effective treatment available for many musculoskeletal conditions. Interestingly, given the symbiotic relationship between muscle and bone, understanding the pathological aetiology and designing regenerative therapies often necessitates integrated research encompassing both muscle and skeletal tissues.  

T‌he REMEDI Musculoskeletal Research Programme

Research teams in REMEDI are investigating both the aetiology of bone disorders, such as osteoporosis and diabetic osteopathy, and regenerative therapies to address bone defect/ fracture repair caused by diease or trauma. For example, researchers are exploring the underlying mechanisms of bone disorders by examining disease-specific progenitor cell populations. In particular they are developing interventional therapies such as novel bone graft substitutes and cellular therapies targetting fracture repair. REMEDI research teams are also developing therapies to tackle muscle damage that occurs as a complication of diabetes. Furthermore, our researchers are investigating the mechansims of muscle wasting during common conditions, such as sarcopenia or cachexia, as well as rare disorders, such as amyotrophic lateral sclerosis (ALS). This research is focused on non-coding RNAs, such as microRNAs as potential therapeutics for muscle wasting, as well as investigating RNAs as potential therapeutics for conditions with no treatment options, such as ALS.  

Relevant Research Groups